Alcresta is a specialty pharmaceutical company that is developing innovative and proprietary enzyme based products for people suffering from compromised pancreatic function such as exocrine pancreatic insufficiency (EPI) or nutrient malabsorption. 

Read more

Alcresta Presents New Data Demonstrating Potential of Proprietary Enzyme-Based Technology to Improve Nutrition in Patients with Exocrine Pancreatic Insufficiency

Read More >

Alcresta Appoints John H. Tucker to Chief Executive Officer

Read More >

Alcresta Announces Agreement with Cystic Fibrosis Foundation Therapeutics to Develop Point-of-Care Nutritional Products

Read More >